The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

June 1, 2026

Conditions
Immune Thrombocytopenia
Interventions
DRUG

Zanubrutinib

Zanubrutinib 80mg qd po, 6 consecutive weeks

DRUG

Dexamethasone

Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)

All Listed Sponsors
collaborator

Beijing Hospital

OTHER_GOV

collaborator

Navy General Hospital, Beijing

OTHER

collaborator

Beijing Aerospace General Hospital

OTHER

collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

Beijing Tongren Hospital

OTHER

lead

Peking University People's Hospital

OTHER